Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 12, 731-733, October 1, 1952]
© 1952 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zeidman, I.
Right arrow Articles by Buss, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zeidman, I.
Right arrow Articles by Buss, J. M.

Transpulmonary Passage of Tumor Cell Emboli*

Irving Zeidman and JoAnne M. Buss

( Department of Pathology, University of Pennsylvania School of Medicine, Philadelphia, Pa.)

Experiments were designed to determine whether tumor cell emboli can pass immediately through the pulmonary circulation. V2 carcinoma and Brown-Pearce carcinoma were used in rabbits, and Walker carcinoma 256 in rats. A suspension of tumor cells was injected into an ear vein while the animal was bled simultaneously through the abdominal aorta. The aortic blood was then injected intravenously into a second animal of the same species. Tumors developing in the second animal indicated immediate passage of tumor cells through the lungs of the first animal. All animals were sacrificed 3–5 weeks after the injection of aortic blood, and a search for tumors was made. Tumors were found with all three types of cancers, indicating that the embolic tumor cells had passed through the lungs without delay. The positive results obtained with Brown-Pearce carcinoma were significantly higher than those found with the V2 carcinoma. This difference in incidence of transpulmonary passage corresponds to the greater tendency of Brown-Pearce carcinoma to metastasize to many organs, in contrast to the behavior of V2 carcinoma which rarely metastasizes beyond the lungs.

It is concluded that tumor cell emboli are able to pass immediately through the pulmonary circulation of both rabbits and rats and that differences in incidence of such activity apparently depend on some as yet unexplained property of the cancer cell. These results suggest that transpulmonary passage of tumor cell emboli probably occurs far more frequently in man than heretofore suspected.

* This investigation was supported by research grants from the Anna Fuller Fund, the Special Research Fund of the Committee on the Advancement of Research of the University of Pennsylvania, and the Division of Research Grants and Fellowships of the National Institutes of Health, U.S. Public Health Service.

Received 6/16/52.


This article has been cited by other articles:


Home page
Endocr. Rev.Home page
R. R. Langley and I. J. Fidler
Tumor Cell-Organ Microenvironment Interactions in the Pathogenesis of Cancer Metastasis
Endocr. Rev., May 1, 2007; 28(3): 297 - 321.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
G. Nicolson and S. Custead
Tumor metastasis is not due to adaptation of cells to a new organ environment
Science, January 8, 1982; 215(4529): 176 - 178.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1952 by the American Association for Cancer Research.